Publication at Faculty of Medicine in Pilsen |
2022
Abstract
Due to the nature of its prolonged effect and kinetics with a certain degree of self-regulation, pegfilgrastim is predestined for planned or prophylactic administration. It is indicated to shorten the duration of neutropenia and the incidence of febrile neutropenia in adult patients receiving cytotoxic chemotherapy for malignancies (excluding chronic myeloid leukemia and myelodysplastic syndrome).
Single subcutaneous application is also an important benefit to patients.